Data / Research funding / California / La Jolla Institute for Immunology
La Jolla Institute for Immunology: 71 NIH awards ($201M), fiscal years 2021 to 2026
La Jolla Institute for Immunology in La Jolla, CA is funded under 71 NIH awards ($201M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- ZPAUY3FQMM26
- State
- California
Awards
71 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Consortium for Immunotherapeutics against Emerging Viral Threats | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $22,996,095 | May 1, 2019 | April 30, 2025 | SAPHIRE, ERICA OLLMANN | reporter.nih.gov |
| Human immune memory to COVID-19, vaccines, and respiratory pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,300,064 | March 11, 2019 | February 28, 2029 | CROTTY, SHANE P | reporter.nih.gov |
| IMMUNE EPITOPE AND ANALYSIS PROGRAM (infectious diseases as result of other diseases) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,428,426 | December 15, 2018 | December 14, 2025 | SETTE, ALESSANDRO | reporter.nih.gov |
| HIPC Data Coordinating Center | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $14,760,228 | April 13, 2022 | March 31, 2027 | PETERS, BJOERN | reporter.nih.gov |
| Respiratory pathogen-specific T cell signatures following vaccination, natural infection, and treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,580,221 | June 1, 2025 | May 31, 2027 | SETTE, ALESSANDRO | reporter.nih.gov |
| Developing computational models to predict the immune response to B. pertussis booster vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,401,756 | March 10, 2020 | February 28, 2025 | PETERS, BJOERN | reporter.nih.gov |
| Large Scale T Cell Epitope Discovery:Global identification of epitopes derived from Zika (ZIKV), Chikungunya (CHIKV) viruses following natural infection and vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,881,220 | September 30, 2019 | September 29, 2024 | MITCHELL, MAYA | reporter.nih.gov |
| THE CANCER EPITOPE DATABASE AND ANALYSIS RESOURCE | NIH | National Cancer Institute | 2021 to 2025 | $4,550,196 | May 5, 2021 | April 30, 2027 | SETTE, ALESSANDRO | reporter.nih.gov |
| Research Resources: Epigenomic and Transcriptomic Profile of Human Immune Cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,524,094 | August 1, 2014 | August 31, 2030 | VIJAYANAND, PANDURANGAN | reporter.nih.gov |
| Maximizing germinal centers and somatic hypermutation to HIV Env immunogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,431,323 | February 1, 2016 | January 31, 2026 | CROTTY, SHANE P | reporter.nih.gov |
| Signal transduction and gene induction in lymphocytes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,374,000 | August 1, 1991 | August 31, 2028 | HOGAN, PATRICK | reporter.nih.gov |
| The TET-DNMT-ASXL1-OGT axis: relevance to clonal hematopoiesis, heterochromatin integrity and cancer | NIH | National Cancer Institute | 2021 to 2025 | $4,334,400 | September 1, 2016 | August 31, 2031 | RAO, ANJANA | reporter.nih.gov |
| Development of a Replicon RNA-based Vaccine against Dengue and Zika | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,590,945 | June 1, 2021 | May 31, 2026 | SHRESTA, SUJAN | reporter.nih.gov |
| Bioactive Metabolites Modulate Immune-Related Adverse Events in Cancer Immunotherapy | NIH | National Cancer Institute | 2021 to 2025 | $3,549,010 | July 8, 2021 | February 28, 2027 | SHARMA, SONIA | reporter.nih.gov |
| NFAT, bZIP proteins, and transcriptional programs in lymphocytes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,369,412 | August 1, 2014 | February 28, 2025 | HOGAN, PATRICK | reporter.nih.gov |
| Investigating the role of TET deficiency in promoting T cell expansion and inflammation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,325,237 | June 7, 2017 | May 31, 2027 | RAO, ANJANA | reporter.nih.gov |
| Maternal Antibody-Mediated Enhancement of Dengue Pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,138,902 | March 5, 2021 | February 28, 2026 | SHRESTA, SUJAN | reporter.nih.gov |
| Immune Cell Interactions in Atherosclerosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $2,867,411 | August 1, 2017 | June 2, 2022 | HEDRICK, CATHERINE C | reporter.nih.gov |
| Large Scale T Cell Epitope Discovery: Proteome-wide characterization of T cell epitopes from Mycobacterium tuberculosis in vaccination and active infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,815,378 | September 30, 2019 | September 29, 2023 | PETERS, BJOERN | reporter.nih.gov |
| The Role of Cytoplasmic and Nuclear THEMIS in Immature and Mature T cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,753,784 | February 14, 2020 | January 31, 2025 | CHEROUTRE, HILDE MC | reporter.nih.gov |
| Studying the function of human genetic variation in the light of 3D genome organization | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,727,161 | August 1, 2018 | July 31, 2028 | AY, FERHAT | reporter.nih.gov |
| Large Scale T Cell Epitope Discovery: Genome-wide characterization of T cell epitopes from Bordetella pertussis in vaccination and natural infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,639,433 | September 30, 2019 | September 29, 2023 | SETTE, ALESSANDRO | reporter.nih.gov |
| Identifying mechanisms and correlates of long-lasting vaccine-induced immunity to whooping cough | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,469,606 | December 6, 2018 | November 30, 2023 | SETTE, ALESSANDRO | reporter.nih.gov |
| LJI Epitope Validation Center: Characterization of epitope-specific T cells responding to food, fungal and inner city allergens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,432,798 | January 1, 2018 | December 31, 2022 | SETTE, ALESSANDRO | reporter.nih.gov |
| Exploring the potential of TET inhibition in cancer immunotherapy | NIH | National Cancer Institute | 2021 to 2024 | $2,169,214 | July 1, 2020 | June 30, 2025 | RAO, ANJANA | reporter.nih.gov |
| SARS-CoV-2-reactive tissue-resident memory T cells in healthy and cancer subjects | NIH | National Cancer Institute | 2022 to 2024 | $2,155,816 | September 30, 2020 | August 31, 2025 | VIJAYANAND, PANDURANGAN | reporter.nih.gov |
| THE IDENTIFICATION AND VALIDATION OF EPITOPES CONSERVED IN VIRAL PATHOGEN FAMILIES WITH PANDEMIC POTENTIAL | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,080,465 | September 30, 2025 | September 29, 2026 | FABRITZKY, BRANDON | reporter.nih.gov |
| IDENTIFICATION AND CHARACTERIZATION OF T CELL EPITOPES FROM BACTERIAL PATHOGENS CAUSING PNEUMONIA | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,079,792 | September 30, 2025 | September 29, 2026 | PETERS, BJOERN | reporter.nih.gov |
| Elucidating the signaling and protein interaction networks of the O-GlcNAc transferase during embryonic stem cell state transitions | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $1,919,433 | August 1, 2022 | May 31, 2027 | MYERS, SAMUEL ANTHONY | reporter.nih.gov |
| CD4 T cell control of cytomegalovirus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,795,779 | February 7, 2019 | January 31, 2025 | BENEDICT, CHRISTOPHER A | reporter.nih.gov |
| A novel strategy for vaccine-induced protection against maternal-to-fetal transmission of Zika virus | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,768,228 | June 7, 2024 | April 30, 2029 | SHRESTA, SUJAN | reporter.nih.gov |
| HIV mRNA vaccine strategies for efficient priming, diversity and durability of immune responses | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,767,184 | April 1, 2024 | March 31, 2027 | RAMEZANI-RAD, PARHAM | reporter.nih.gov |
| Training in Immunological Mechanisms | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,717,051 | August 1, 2016 | July 31, 2026 | CROFT, MICHAEL | reporter.nih.gov |
| Stimulating Neo-Antigen Specific T Cell Responses in Head and Neck Cancers | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2022 | $1,687,410 | September 19, 2018 | August 31, 2024 | SCHOENBERGER, STEPHEN PHILIP | reporter.nih.gov |
| The role of TRAIL in immune control of cytomegalovirus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,647,000 | January 10, 2013 | May 31, 2025 | BENEDICT, CHRISTOPHER A | reporter.nih.gov |
| A Treg cell-intrinsic CTLA4-PKC-eta signaling pathway mediating contact-dependent suppression of tumor immunity: A novel target for cancer immunotherapy | NIH | National Cancer Institute | 2021 to 2023 | $1,548,265 | December 1, 2018 | November 30, 2023 | CROFT, MICHAEL | reporter.nih.gov |
| Vascular macrophages and T cells in atherosclerosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,496,145 | March 18, 2019 | July 31, 2022 | LEY, KLAUS F. | reporter.nih.gov |
| Integrated Functional Histopathology of the Diabetic Human Pancreas | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,398,000 | December 7, 2017 | November 30, 2022 | VON HERRATH, MATTHIAS G. | reporter.nih.gov |
| Dysregulation of TET dioxygenase function as a source of aberrant transposable element expression during human aging | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,297,837 | March 20, 2024 | February 28, 2029 | RAO, ANJANA | reporter.nih.gov |
| Histamine-Releasing Factor Oligomers in Food Allergy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,268,662 | August 1, 2019 | July 31, 2024 | KAWAKAMI, TOSHIAKI | reporter.nih.gov |
| Towards a predictive understanding of influenza immunity through experimental data integration, iterative model development, and rigorous assessment of model quality | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,246,617 | December 19, 2024 | November 30, 2029 | PETERS, BJOERN | reporter.nih.gov |
| Host nutrients permit immune evasion of NKT cell anti-bacterial responses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,230,778 | January 17, 2018 | December 31, 2022 | KRONENBERG, MITCHELL | reporter.nih.gov |
| Genetic studies linking LSP1 function in T cells to Inflammatory Bowel Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,151,436 | April 1, 2023 | January 31, 2028 | SCHMIEDEL, BENJAMIN JOACHIM | reporter.nih.gov |
| Proteome-wide base editor screens to assess phosphorylation site functionality in immunosenescence | NIH | National Cancer Institute | 2024 to 2025 | $1,139,953 | May 1, 2024 | January 31, 2029 | MYERS, SAMUEL ANTHONY | reporter.nih.gov |
| Specificity, Phenotype and Function of Pancreatic CD8 T Cells in Human Type 1 Diabetes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $999,000 | May 2, 2011 | February 15, 2024 | QUESADA MASACHS, ESTEFANIA | reporter.nih.gov |
| Role of a Novel Interferon Responsive T Cell Subset in Allergy and Asthma | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $915,000 | September 20, 2022 | July 31, 2024 | SEUMOIS, GREGORY | reporter.nih.gov |
| CD4 T cell, germinal center, and antibody response defects in recurrent tonsillitis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $900,000 | June 14, 2018 | May 31, 2024 | CROTTY, SHANE P | reporter.nih.gov |
| Epigenome-wide association study of childhood asthma | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $784,641 | January 1, 2017 | December 31, 2022 | VIJAYANAND, PANDURANGAN | reporter.nih.gov |
| TWEAK and Skin Inflammation | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $776,160 | July 18, 2018 | October 31, 2023 | CROFT, MICHAEL | reporter.nih.gov |
| Next Generation Crispr Ready, HLA Class I and II Transgenic Mouse Platform | NIH | Office of the Director, National Institutes of Health | 2025 | $775,888 | May 1, 2025 | April 30, 2029 | SHRESTA, SUJAN | reporter.nih.gov |
| LIGHT/TNFSF14 in allergic esophagitis remodeling | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $568,901 | April 1, 2018 | August 31, 2022 | CROFT, MICHAEL | reporter.nih.gov |
| Structure of the SARS-CoV-2 Nucleocapsid: building block to viral capsid | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $515,577 | July 5, 2023 | June 30, 2025 | SAPHIRE, ERICA OLLMANN | reporter.nih.gov |
| Automated Multiscale Super-resolution Confocal Microscope | NIH | Office of the Director, National Institutes of Health | 2022 | $514,425 | September 15, 2022 | September 14, 2023 | KIOSSES, BILL WILLIAM | reporter.nih.gov |
| Linking specific phosphorylation events to distinct transcriptional states | NIH | National Center for Advancing Translational Sciences | 2024 | $509,784 | June 1, 2024 | May 31, 2026 | MYERS, SAM ANTHONY | reporter.nih.gov |
| Dynamic analysis of beta cell attacks in response to virus infection in Human pancreatic slices | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $503,250 | March 27, 2023 | February 28, 2025 | BENKAHLA, MEHDI | reporter.nih.gov |
| Experimental identification of functional GWAS variants linked to COVID-19 severity in immune cells | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $503,250 | May 22, 2023 | April 30, 2025 | SCHMIEDEL, BENJAMIN JOACHIM | reporter.nih.gov |
| Filovirus nucleocapsid assembly, caught in the act, by in situ structural biology | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $503,250 | June 1, 2024 | April 30, 2026 | SAPHIRE, ERICA OLLMANN | reporter.nih.gov |
| Illuminating Lujo virus glycoprotein structure, receptor engagement and neutralizing antibody epitopes | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $496,388 | November 24, 2023 | October 31, 2025 | HASTIE, KATHRYN MARIE | reporter.nih.gov |
| What is the human antibody response to measles virus vaccination? | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $496,388 | December 1, 2023 | October 31, 2025 | SAPHIRE, ERICA OLLMANN | reporter.nih.gov |
| Understanding pH-dependent receptor utilization of Lassa virus | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $496,388 | May 24, 2024 | March 31, 2026 | LI, HAOYANG | reporter.nih.gov |
| Immune Regulation by Deubiquitination | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $450,000 | September 19, 2018 | February 28, 2022 | CROFT, MICHAEL | reporter.nih.gov |
| Using Common Fund datasets for prioritization of disease-associated genetic variants | NIH | Office of the Director, National Institutes of Health | 2022 | $366,000 | September 20, 2022 | September 19, 2024 | AY, FERHAT | reporter.nih.gov |
| A novel CD4+ T cell subset associated with allergy protection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $299,500 | July 11, 2023 | July 31, 2024 | SEUMOIS, GREGORY | reporter.nih.gov |
| Crosstalk between FceRI and MAVS signaling pathways in mast cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $228,750 | May 22, 2020 | April 30, 2022 | KAWAKAMI, TOSHIAKI | reporter.nih.gov |
| The role of Alternaria fungal sensitization in asthma pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $175,000 | May 1, 2025 | April 30, 2026 | VIJAYANAND, PANDURANGAN | reporter.nih.gov |
| Tumor suppressive functions of TET proteins in B cell malignancies: role of G-quadruplex structures | NIH | National Cancer Institute | 2021 | $144,720 | March 10, 2020 | February 28, 2022 | SHUKLA, VIPUL | reporter.nih.gov |
| Protective Role of Nonclassical Monocytes in Immunotherapies for Solid Cancers | NIH | National Cancer Institute | 2021 | $136,148 | April 1, 2018 | March 31, 2022 | HEDRICK, CATHERINE C | reporter.nih.gov |
| Evaluation of T follicular regulatory cells as novel cellular targets of cancer immunotherapy | NIH | National Cancer Institute | 2023 | $102,450 | July 1, 2023 | November 30, 2023 | ESCHWEILER, SIMON | reporter.nih.gov |
| The Role of Intestinal Epithelial Cells in the Generation of Protective CD4 Cytotoxic T Lymphocytes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $54,316 | March 1, 2020 | May 31, 2022 | CHEN, ANGELINE | reporter.nih.gov |
| Rabies virus glycoprotein structure determination and receptor binding interactions | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $5,714 | July 1, 2019 | July 31, 2021 | CALLAWAY, HEATHER M | reporter.nih.gov |
| Roles of vaccine perturbations on germinal center dynamics | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1 | June 5, 2025 | June 6, 2025 | FREEMAN, BRIAN LUIS | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 31 | $31,092,722 | 0 | $0 |
| 2024 | 36 | $31,397,852 | 0 | $0 |
| 2023 | 36 | $39,232,674 | 0 | $0 |
| 2022 | 42 | $46,174,130 | 0 | $0 |
| 2021 | 44 | $53,129,676 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 42 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 42 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 42 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 42 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 42 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 42 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 42 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 42 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 42 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 42 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 42 awards here |
| Immune Tolerance Network (UM1 Clinical Trial Required) | RFA-AI-28-005 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 42 awards here |
| Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed) | RFA-AI-28-012 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 42 awards here |
| Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) | RFA-AI-28-024 | NIH | 93.855 | February 11, 2027 | Not listed | Same assistance listing 93.855 as 42 awards here |
| NLM Institutional Grants for Research Training in Biomedical Informatics, Data Science, and AI (T15 Independent Clinical Trial Not Allowed) | RFA-LM-28-001 | NIH | 93.855 | February 11, 2027 | $775,000 | Same assistance listing 93.855 as 42 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 42 awards here |
| NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) | PA-27-102 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 42 awards here |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 42 awards here |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) | PA-24-185 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 42 awards here |
| Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required) | PA-24-187 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 42 awards here |
Topics of its NIH awards
- Infectious Diseases
- Genetics
- Prevention
- Biotechnology
- Emerging Infectious Diseases
- Immunization
- Vaccine Related
- Clinical Research
- Rare Diseases
- Biodefense and Related Countermeasures
- Immunotherapy
- Cancer
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.